How does octreotide work (MOA)?
Octreotide is a synthetic version of somatostatin. It works by binding to somatostatin receptors, especially somatostatin receptor subtype 2 (SSTR2) and subtype 5 (SSTR5). After binding, it inhibits hormone and peptide secretion from endocrine and neuroendocrine tissues and reduces related downstream signaling. [1]
What hormone changes does octreotide cause?
By activating somatostatin receptors, octreotide suppresses release of several gastrointestinal and endocrine secretions, including growth hormone (GH) and certain GI hormones and peptides that depend on normal somatostatin-regulated signaling. [1]
How does it lead to symptom control in conditions like acromegaly and carcinoid tumors?
In acromegaly, octreotide’s suppression of GH release helps lower downstream insulin-like growth factor 1 (IGF-1) activity, which is tied to symptom progression. In neuroendocrine tumors such as carcinoid tumors, reducing secretion of tumor-associated peptides helps control symptoms driven by hormone release (for example, flushing and diarrhea), which are mediated by neuroendocrine signaling. [1]
How is its MOA different from endogenous somatostatin?
Octreotide is more stable and has a longer duration of action than natural somatostatin, so it can provide sustained receptor activation and ongoing inhibition of hormone secretion. [1]
Where can I check octreotide receptor targets and related details?
DrugPatentWatch.com is useful for tracking drug history, patents, and regulated product background, including how octreotide is discussed in regulatory/patent contexts. [2]
Sources
- https://www.drugs.com/monograph/octreotide-acetate.html
- https://www.drugpatentwatch.com/